Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Retrospective Analysis of Comorbidities Associated with Myasthenia Gravis
Neuromuscular and Clinical Neurophysiology (EMG)
P4 - Poster Session 4 (5:30 PM-6:30 PM)
1-007
To assess the development of comorbidities in newly diagnosed MG within the first 12 months.
Myasthenia gravis (MG) is a chronic condition requiring longterm immunosuppressive therapy. The development of comorbid conditions can impact MG treatment and prognosis.
This is a retrospective chart review of all adult MG patients whose data was acquired from 2011-2015 and had at least a year followup in our clinic. The breakdown of 70 patients included (39 men, 31 women; mean age: 62 years, range: 20-97) is 67 Caucasian, 3 African American, 47 seropositive, 6 thymectomy, 3 Myasthenia Gravis Foundation of America (MGFA) class 1, 29 MGFA class 2a, 11 MGFA class 2b, 20 MGFA class 3a, 6 MGFA class 3b, 1 MGFA class 4a, 43 on prednisone, 4 on prednisone and steroid-sparing agent, 15 on steroid-sparing agent alone, 5 on maintenance IVIg, and 10 on pyridostigmine alone.
Of those 70 patients, 35 comorbid events were experienced. Steroid and immunosuppressive related events were the most frequent comprising 31.4%, of which osteoporosis was most common (p=0.0030). Infections and neurological events comprised 28.6% and 25.7% respectively, with pulmonary infections and peripheral neuropathy being the most common. Other comorbid events accounted for 14%, which included chronic obstructive pulmonary disease, stroke, acute kidney injury, gastrointestinal bleed, and hypothyroidism. Older patients tended to have significantly more comorbid events (p=0.0594).
In conclusion, many patients diagnosed with MG experience comorbid events within the first 12 months, most frequently including steroid and immunosuppressive related complications followed closely by infections and other neurological conditions.
Authors/Disclosures
Brian Blankenship, MD
PRESENTER 		Dr. Blankenship has nothing to disclose.
Raghav Govindarajan, MD, FÂ鶹´«Ã½Ó³»­ (HSHS St. Elizabeth Medical Group) Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for MT pharma. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Catalyst. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche . Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amicus. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Govindarajan has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Alexion. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for MT pharma . Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Catalyst. Dr. Govindarajan has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Argenx. Dr. Govindarajan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biohaven. Dr. Govindarajan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for UCB. Dr. Govindarajan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Takeda. Dr. Govindarajan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Abbvie. The institution of Dr. Govindarajan has received research support from Band of Hope . The institution of Dr. Govindarajan has received research support from Alexion. Dr. Govindarajan has received publishing royalties from a publication relating to health care.